Overview: NGS Motor Neuron Disease Sequencing TestIntroduction: The NGS Motor Neuron Disease Sequencing Test sequences genes to diagnose motor neuron disease, causing muscle weakness. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected motor neuron diseases, such as amyotrophic lateral sclerosis (ALS).
Other Names: Motor Neuron Disease NGS Assay, SOD1/C9orf72 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Motor neuron disease sequencing began in the 1990s with ALS research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose motor neuron disease, guides treatment, and evaluates patients with muscle weakness.
Test Parameters: 1. Motor Neuron Disease Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of muscle weakness, fasciculations, or motor neuron disease symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document muscle weakness, fasciculations, dysarthria, or family history of motor neuron disease. Include current medications, especially riluzole.
Consent: Written consent required, detailing the tests purpose, motor neuron disease implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze motor neuron disease genes (e.g., SOD1, C9orf72). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for motor neuron disease diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm motor neuron disease, guiding supportive care or clinical trials. Negative results may require EMG testing.
Specialist Consultation: Consult a neurologist for result interpretation and treatment planning.
Additional Supporting Tests: EMG, nerve conduction studies, or brain MRI to confirm motor neuron disease diagnosis.
Test Limitations: Not all motor neuron diseases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN ALS Guidelines, 2023; Neurology, Brown RH, 2022.
